Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID-19 cases treated with Sotrovimab in the community in England Article Swipe

PDF

Katie Harman , Sophie Nash , Harriet Webster , Natalie Groves , Jo Hardstaff , Jessica R. E. Bridgen , Paula Blomquist , Russell Hope , Efejiro Ashano , Richard Myers , Sakib Rokadiya , Susan Hopkins , Colin Brown , Meera Chand , Gavin Dabrera , Simon Thelwall ·

YOU? · · 2022 · Open Access · · DOI: https://doi.org/10.1101/2022.10.21.22281171

Objectives Sotrovimab is one of several therapeutic agents that have been licensed to treat people at risk of severe outcomes following COVID-19 infection. However, there are concerns that it has reduced efficacy to treat people with the BA.2 sub-lineage of the Omicron (B.1.1.529) SARS-CoV-2 variant. We compared individuals with the BA.1 or BA.2 sub-lineage of the Omicron variant treated Sotrovimab in the community to assess their risk of hospital admission. Methods We performed a retrospective cohort study of individuals treated with Sotrovimab in the community and either had BA.1 or BA.2 variant classification. Results Using a Stratified Cox regression model it was estimated that the hazard ratios (HR) of hospital admission with a length of stay of two or more days was 1.17 for BA.2 compared to BA.1 (95% CI 0.74-1.86) and for such admissions where COVID-19 ICD-10 codes was recorded the HR was 0.98 (95% CI 0.58-1.65). Conclusion These results suggest that the risk of hospital admission is similar between BA.1 and BA.2 cases treated with Sotrovimab in the community.

Related Topics

Infectious Diseases (Medical Specialty)

Concepts

Medicine Coronavirus disease 2019 (COVID-19) Retrospective cohort study Hazard ratio Proportional hazards model Cohort Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Hospital admission Internal medicine Community hospital Pediatrics Demography Confidence interval Disease Psychiatry Sociology Infectious disease (medical specialty)

Metadata

Type: preprint
Language: en
Landing Page: https://doi.org/10.1101/2022.10.21.22281171
PDF: https://www.medrxiv.org/content/medrxiv/early/2022/10/22/2022.10.21.22281171.full.pdf
OA Status: green
Cited By: 17
References: 7
Related Works: 10
OpenAlex ID: https://openalex.org/W4307523553

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4307523553

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1101/2022.10.21.22281171

Digital Object Identifier
Title: Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID-19 cases treated with Sotrovimab in the community in England

Work title
Type: preprint

OpenAlex work type
Language: en

Primary language
Publication year: 2022

Year of publication
Publication date: 2022-10-22

Full publication date if available
Authors: Katie Harman, Sophie Nash, Harriet Webster, Natalie Groves, Jo Hardstaff, Jessica R. E. Bridgen, Paula Blomquist, Russell Hope, Efejiro Ashano, Richard Myers, Sakib Rokadiya, Susan Hopkins, Colin Brown, Meera Chand, Gavin Dabrera, Simon Thelwall

List of authors in order
Landing page: https://doi.org/10.1101/2022.10.21.22281171

Publisher landing page
PDF URL: https://www.medrxiv.org/content/medrxiv/early/2022/10/22/2022.10.21.22281171.full.pdf

Direct link to full text PDF
Open access: Yes

Whether a free full text is available
OA status: green

Open access status per OpenAlex
OA URL: https://www.medrxiv.org/content/medrxiv/early/2022/10/22/2022.10.21.22281171.full.pdf

Direct OA link when available
Concepts: Medicine, Coronavirus disease 2019 (COVID-19), Retrospective cohort study, Hazard ratio, Proportional hazards model, Cohort, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Hospital admission, Internal medicine, Community hospital, Pediatrics, Demography, Confidence interval, Disease, Psychiatry, Sociology, Infectious disease (medical specialty)

Top concepts (fields/topics) attached by OpenAlex
Cited by: 17

Total citation count in OpenAlex
Citations by year (recent): 2024: 3, 2023: 13, 2022: 1

Per-year citation counts (last 5 years)
References (count): 7

Number of works referenced by this work
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W4307523553
doi	https://doi.org/10.1101/2022.10.21.22281171
ids.doi	https://doi.org/10.1101/2022.10.21.22281171
ids.openalex	https://openalex.org/W4307523553
fwci	2.12809052
type	preprint
title	Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID-19 cases treated with Sotrovimab in the community in England
biblio.issue
biblio.volume
biblio.last_page
biblio.first_page
topics[0].id	https://openalex.org/T10118
topics[0].field.id	https://openalex.org/fields/27
topics[0].field.display_name	Medicine
topics[0].score	0.9998999834060669
topics[0].domain.id	https://openalex.org/domains/4
topics[0].domain.display_name	Health Sciences
topics[0].subfield.id	https://openalex.org/subfields/2725
topics[0].subfield.display_name	Infectious Diseases
topics[0].display_name	SARS-CoV-2 and COVID-19 Research
topics[1].id	https://openalex.org/T10041
topics[1].field.id	https://openalex.org/fields/27
topics[1].field.display_name	Medicine
topics[1].score	0.9966999888420105
topics[1].domain.id	https://openalex.org/domains/4
topics[1].domain.display_name	Health Sciences
topics[1].subfield.id	https://openalex.org/subfields/2725
topics[1].subfield.display_name	Infectious Diseases
topics[1].display_name	COVID-19 Clinical Research Studies
topics[2].id	https://openalex.org/T11914
topics[2].field.id	https://openalex.org/fields/27
topics[2].field.display_name	Medicine
topics[2].score	0.9941999912261963
topics[2].domain.id	https://openalex.org/domains/4
topics[2].domain.display_name	Health Sciences
topics[2].subfield.id	https://openalex.org/subfields/2730
topics[2].subfield.display_name	Oncology
topics[2].display_name	PARP inhibition in cancer therapy
is_xpac	False
apc_list
apc_paid
concepts[0].id	https://openalex.org/C71924100
concepts[0].level	0
concepts[0].score	0.6867448091506958
concepts[0].wikidata	https://www.wikidata.org/wiki/Q11190
concepts[0].display_name	Medicine
concepts[1].id	https://openalex.org/C3008058167
concepts[1].level	4
concepts[1].score	0.6791456341743469
concepts[1].wikidata	https://www.wikidata.org/wiki/Q84263196
concepts[1].display_name	Coronavirus disease 2019 (COVID-19)
concepts[2].id	https://openalex.org/C167135981
concepts[2].level	2
concepts[2].score	0.6116902828216553
concepts[2].wikidata	https://www.wikidata.org/wiki/Q2146302
concepts[2].display_name	Retrospective cohort study
concepts[3].id	https://openalex.org/C207103383
concepts[3].level	3
concepts[3].score	0.5946519374847412
concepts[3].wikidata	https://www.wikidata.org/wiki/Q3930246
concepts[3].display_name	Hazard ratio
concepts[4].id	https://openalex.org/C50382708
concepts[4].level	2
concepts[4].score	0.5318448543548584
concepts[4].wikidata	https://www.wikidata.org/wiki/Q223218
concepts[4].display_name	Proportional hazards model
concepts[5].id	https://openalex.org/C72563966
concepts[5].level	2
concepts[5].score	0.5097467303276062
concepts[5].wikidata	https://www.wikidata.org/wiki/Q1303415
concepts[5].display_name	Cohort
concepts[6].id	https://openalex.org/C3007834351
concepts[6].level	5
concepts[6].score	0.4356447756290436
concepts[6].wikidata	https://www.wikidata.org/wiki/Q82069695
concepts[6].display_name	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
concepts[7].id	https://openalex.org/C3019871722
concepts[7].level	2
concepts[7].score	0.4312403202056885
concepts[7].wikidata	https://www.wikidata.org/wiki/Q718944
concepts[7].display_name	Hospital admission
concepts[8].id	https://openalex.org/C126322002
concepts[8].level	1
concepts[8].score	0.42277318239212036
concepts[8].wikidata	https://www.wikidata.org/wiki/Q11180
concepts[8].display_name	Internal medicine
concepts[9].id	https://openalex.org/C2779861157
concepts[9].level	2
concepts[9].score	0.4132983684539795
concepts[9].wikidata	https://www.wikidata.org/wiki/Q5154967
concepts[9].display_name	Community hospital
concepts[10].id	https://openalex.org/C187212893
concepts[10].level	1
concepts[10].score	0.33204132318496704
concepts[10].wikidata	https://www.wikidata.org/wiki/Q123028
concepts[10].display_name	Pediatrics
concepts[11].id	https://openalex.org/C149923435
concepts[11].level	1
concepts[11].score	0.3236236572265625
concepts[11].wikidata	https://www.wikidata.org/wiki/Q37732
concepts[11].display_name	Demography
concepts[12].id	https://openalex.org/C44249647
concepts[12].level	2
concepts[12].score	0.15848252177238464
concepts[12].wikidata	https://www.wikidata.org/wiki/Q208498
concepts[12].display_name	Confidence interval
concepts[13].id	https://openalex.org/C2779134260
concepts[13].level	2
concepts[13].score	0.07958206534385681
concepts[13].wikidata	https://www.wikidata.org/wiki/Q12136
concepts[13].display_name	Disease
concepts[14].id	https://openalex.org/C118552586
concepts[14].level	1
concepts[14].score	0.07667398452758789
concepts[14].wikidata	https://www.wikidata.org/wiki/Q7867
concepts[14].display_name	Psychiatry
concepts[15].id	https://openalex.org/C144024400
concepts[15].level	0
concepts[15].score	0.0
concepts[15].wikidata	https://www.wikidata.org/wiki/Q21201
concepts[15].display_name	Sociology
concepts[16].id	https://openalex.org/C524204448
concepts[16].level	3
concepts[16].score	0.0
concepts[16].wikidata	https://www.wikidata.org/wiki/Q788926
concepts[16].display_name	Infectious disease (medical specialty)
keywords[0].id	https://openalex.org/keywords/medicine
keywords[0].score	0.6867448091506958
keywords[0].display_name	Medicine
keywords[1].id	https://openalex.org/keywords/coronavirus-disease-2019
keywords[1].score	0.6791456341743469
keywords[1].display_name	Coronavirus disease 2019 (COVID-19)
keywords[2].id	https://openalex.org/keywords/retrospective-cohort-study
keywords[2].score	0.6116902828216553
keywords[2].display_name	Retrospective cohort study
keywords[3].id	https://openalex.org/keywords/hazard-ratio
keywords[3].score	0.5946519374847412
keywords[3].display_name	Hazard ratio
keywords[4].id	https://openalex.org/keywords/proportional-hazards-model
keywords[4].score	0.5318448543548584
keywords[4].display_name	Proportional hazards model
keywords[5].id	https://openalex.org/keywords/cohort
keywords[5].score	0.5097467303276062
keywords[5].display_name	Cohort
keywords[6].id	https://openalex.org/keywords/severe-acute-respiratory-syndrome-coronavirus-2
keywords[6].score	0.4356447756290436
keywords[6].display_name	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
keywords[7].id	https://openalex.org/keywords/hospital-admission
keywords[7].score	0.4312403202056885
keywords[7].display_name	Hospital admission
keywords[8].id	https://openalex.org/keywords/internal-medicine
keywords[8].score	0.42277318239212036
keywords[8].display_name	Internal medicine
keywords[9].id	https://openalex.org/keywords/community-hospital
keywords[9].score	0.4132983684539795
keywords[9].display_name	Community hospital
keywords[10].id	https://openalex.org/keywords/pediatrics
keywords[10].score	0.33204132318496704
keywords[10].display_name	Pediatrics
keywords[11].id	https://openalex.org/keywords/demography
keywords[11].score	0.3236236572265625
keywords[11].display_name	Demography
keywords[12].id	https://openalex.org/keywords/confidence-interval
keywords[12].score	0.15848252177238464
keywords[12].display_name	Confidence interval
keywords[13].id	https://openalex.org/keywords/disease
keywords[13].score	0.07958206534385681
keywords[13].display_name	Disease
keywords[14].id	https://openalex.org/keywords/psychiatry
keywords[14].score	0.07667398452758789
keywords[14].display_name	Psychiatry
language	en
locations[0].id	doi:10.1101/2022.10.21.22281171
locations[0].is_oa	True
locations[0].source.id	https://openalex.org/S4306402567
locations[0].source.issn
locations[0].source.type	repository
locations[0].source.is_oa	False
locations[0].source.issn_l
locations[0].source.is_core	False
locations[0].source.is_in_doaj	False
locations[0].source.display_name	bioRxiv (Cold Spring Harbor Laboratory)
locations[0].source.host_organization	https://openalex.org/I2750212522
locations[0].source.host_organization_name	Cold Spring Harbor Laboratory
locations[0].source.host_organization_lineage	https://openalex.org/I2750212522
locations[0].license	cc-by
locations[0].pdf_url	https://www.medrxiv.org/content/medrxiv/early/2022/10/22/2022.10.21.22281171.full.pdf
locations[0].version	acceptedVersion
locations[0].raw_type	posted-content
locations[0].license_id	https://openalex.org/licenses/cc-by
locations[0].is_accepted	True
locations[0].is_published	False
locations[0].raw_source_name
locations[0].landing_page_url	https://doi.org/10.1101/2022.10.21.22281171
indexed_in	crossref
authorships[0].author.id	https://openalex.org/A5054599845
authorships[0].author.orcid	https://orcid.org/0000-0003-1387-0200
authorships[0].author.display_name	Katie Harman
authorships[0].affiliations[0].raw_affiliation_string	UKHSA COVID-9 National Epidemiology Cell, London, NW9 5EQ, England
authorships[0].author_position	first
authorships[0].raw_author_name	Katie Harman
authorships[0].is_corresponding	True
authorships[0].raw_affiliation_strings	UKHSA COVID-9 National Epidemiology Cell, London, NW9 5EQ, England
authorships[1].author.id	https://openalex.org/A5034927280
authorships[1].author.orcid	https://orcid.org/0000-0002-7717-6982
authorships[1].author.display_name	Sophie Nash
authorships[1].affiliations[0].raw_affiliation_string	UKHSA COVID-9 National Epidemiology Cell, London, NW9 5EQ, England
authorships[1].author_position	middle
authorships[1].raw_author_name	Sophie G Nash
authorships[1].is_corresponding	False
authorships[1].raw_affiliation_strings	UKHSA COVID-9 National Epidemiology Cell, London, NW9 5EQ, England
authorships[2].author.id	https://openalex.org/A5070668121
authorships[2].author.orcid	https://orcid.org/0000-0002-2145-8884
authorships[2].author.display_name	Harriet Webster
authorships[2].affiliations[0].raw_affiliation_string	UKHSA COVID-9 National Epidemiology Cell, London, NW9 5EQ, England
authorships[2].author_position	middle
authorships[2].raw_author_name	Harriet H Webster
authorships[2].is_corresponding	False
authorships[2].raw_affiliation_strings	UKHSA COVID-9 National Epidemiology Cell, London, NW9 5EQ, England
authorships[3].author.id	https://openalex.org/A5065097521
authorships[3].author.orcid	https://orcid.org/0000-0002-3832-3484
authorships[3].author.display_name	Natalie Groves
authorships[3].countries	GB
authorships[3].affiliations[0].institution_ids	https://openalex.org/I4210143578
authorships[3].affiliations[0].raw_affiliation_string	UKHSA Genomics and Public Health Analysis, London, NW9 5EQ, England
authorships[3].institutions[0].id	https://openalex.org/I4210143578
authorships[3].institutions[0].ror	https://ror.org/04rxxfz69
authorships[3].institutions[0].type	other
authorships[3].institutions[0].lineage	https://openalex.org/I1311074006, https://openalex.org/I4210143578
authorships[3].institutions[0].country_code	GB
authorships[3].institutions[0].display_name	Genomics England
authorships[3].author_position	middle
authorships[3].raw_author_name	Natalie Groves
authorships[3].is_corresponding	False
authorships[3].raw_affiliation_strings	UKHSA Genomics and Public Health Analysis, London, NW9 5EQ, England
authorships[4].author.id	https://openalex.org/A5057470790
authorships[4].author.orcid	https://orcid.org/0000-0003-3345-209X
authorships[4].author.display_name	Jo Hardstaff
authorships[4].affiliations[0].raw_affiliation_string	UKHSA Outbreak Surveillance Team, London, NW9 EQ, England
authorships[4].author_position	middle
authorships[4].raw_author_name	Jo Hardstaff
authorships[4].is_corresponding	False
authorships[4].raw_affiliation_strings	UKHSA Outbreak Surveillance Team, London, NW9 EQ, England
authorships[5].author.id	https://openalex.org/A5021956260
authorships[5].author.orcid	https://orcid.org/0000-0001-5497-2700
authorships[5].author.display_name	Jessica R. E. Bridgen
authorships[5].affiliations[0].raw_affiliation_string	UKHSA Outbreak Surveillance Team, London, NW9 EQ, England
authorships[5].author_position	middle
authorships[5].raw_author_name	Jessica Bridgen
authorships[5].is_corresponding	False
authorships[5].raw_affiliation_strings	UKHSA Outbreak Surveillance Team, London, NW9 EQ, England
authorships[6].author.id	https://openalex.org/A5085156593
authorships[6].author.orcid	https://orcid.org/0000-0002-3962-4211
authorships[6].author.display_name	Paula Blomquist
authorships[6].affiliations[0].raw_affiliation_string	UKHSA Outbreak Surveillance Team, London, NW9 EQ, England
authorships[6].author_position	middle
authorships[6].raw_author_name	Paula B Blomquist
authorships[6].is_corresponding	False
authorships[6].raw_affiliation_strings	UKHSA Outbreak Surveillance Team, London, NW9 EQ, England
authorships[7].author.id	https://openalex.org/A5039878003
authorships[7].author.orcid	https://orcid.org/0000-0003-2838-6833
authorships[7].author.display_name	Russell Hope
authorships[7].affiliations[0].raw_affiliation_string	UKHSA COVID-9 National Epidemiology Cell, London, NW9 5EQ, England
authorships[7].author_position	middle
authorships[7].raw_author_name	Russell Hope
authorships[7].is_corresponding	False
authorships[7].raw_affiliation_strings	UKHSA COVID-9 National Epidemiology Cell, London, NW9 5EQ, England
authorships[8].author.id	https://openalex.org/A5028537387
authorships[8].author.orcid	https://orcid.org/0000-0003-4746-282X
authorships[8].author.display_name	Efejiro Ashano
authorships[8].affiliations[0].raw_affiliation_string	UKHSA HCAI, Fungal, AMR, AMU & Sepsis Division, London, NW 5EQ, England
authorships[8].author_position	middle
authorships[8].raw_author_name	Efejiro Ashano
authorships[8].is_corresponding	False
authorships[8].raw_affiliation_strings	UKHSA HCAI, Fungal, AMR, AMU & Sepsis Division, London, NW 5EQ, England
authorships[9].author.id	https://openalex.org/A5062024371
authorships[9].author.orcid	https://orcid.org/0000-0003-4269-1164
authorships[9].author.display_name	Richard Myers
authorships[9].countries	GB
authorships[9].affiliations[0].institution_ids	https://openalex.org/I4210143578
authorships[9].affiliations[0].raw_affiliation_string	UKHSA Genomics and Public Health Analysis, London, NW9 5EQ, England
authorships[9].institutions[0].id	https://openalex.org/I4210143578
authorships[9].institutions[0].ror	https://ror.org/04rxxfz69
authorships[9].institutions[0].type	other
authorships[9].institutions[0].lineage	https://openalex.org/I1311074006, https://openalex.org/I4210143578
authorships[9].institutions[0].country_code	GB
authorships[9].institutions[0].display_name	Genomics England
authorships[9].author_position	middle
authorships[9].raw_author_name	Richard Myers
authorships[9].is_corresponding	False
authorships[9].raw_affiliation_strings	UKHSA Genomics and Public Health Analysis, London, NW9 5EQ, England
authorships[10].author.id	https://openalex.org/A5080466143
authorships[10].author.orcid	https://orcid.org/0000-0003-2955-4907
authorships[10].author.display_name	Sakib Rokadiya
authorships[10].affiliations[0].raw_affiliation_string	UKHSA COVID-19 Therapeutics, London, NW9 5EQ, England
authorships[10].author_position	middle
authorships[10].raw_author_name	Sakib Rokadiya
authorships[10].is_corresponding	False
authorships[10].raw_affiliation_strings	UKHSA COVID-19 Therapeutics, London, NW9 5EQ, England
authorships[11].author.id	https://openalex.org/A5030902266
authorships[11].author.orcid	https://orcid.org/0000-0001-5179-5702
authorships[11].author.display_name	Susan Hopkins
authorships[11].affiliations[0].raw_affiliation_string	UKHSA Chief Medical Advisor, London, NW9 5EQ, England
authorships[11].author_position	middle
authorships[11].raw_author_name	Susan Hopkins
authorships[11].is_corresponding	False
authorships[11].raw_affiliation_strings	UKHSA Chief Medical Advisor, London, NW9 5EQ, England
authorships[12].author.id	https://openalex.org/A5074638608
authorships[12].author.orcid	https://orcid.org/0000-0003-4776-3403
authorships[12].author.display_name	Colin Brown
authorships[12].affiliations[0].raw_affiliation_string	UKHSA HCAI, Fungal, AMR, AMU & Sepsis Division & NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, London, NW9 5EQ, England
authorships[12].author_position	middle
authorships[12].raw_author_name	Colin S Brown
authorships[12].is_corresponding	False
authorships[12].raw_affiliation_strings	UKHSA HCAI, Fungal, AMR, AMU & Sepsis Division & NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, London, NW9 5EQ, England
authorships[13].author.id	https://openalex.org/A5067682457
authorships[13].author.orcid	https://orcid.org/0000-0001-9697-0340
authorships[13].author.display_name	Meera Chand
authorships[13].countries	GB
authorships[13].affiliations[0].institution_ids	https://openalex.org/I4210143578
authorships[13].affiliations[0].raw_affiliation_string	UKHSA Genomics and Public Health Analysis, London, NW9 5EQ, England
authorships[13].institutions[0].id	https://openalex.org/I4210143578
authorships[13].institutions[0].ror	https://ror.org/04rxxfz69
authorships[13].institutions[0].type	other
authorships[13].institutions[0].lineage	https://openalex.org/I1311074006, https://openalex.org/I4210143578
authorships[13].institutions[0].country_code	GB
authorships[13].institutions[0].display_name	Genomics England
authorships[13].author_position	middle
authorships[13].raw_author_name	Meera Chand
authorships[13].is_corresponding	False
authorships[13].raw_affiliation_strings	UKHSA Genomics and Public Health Analysis, London, NW9 5EQ, England
authorships[14].author.id	https://openalex.org/A5084296936
authorships[14].author.orcid	https://orcid.org/0000-0003-4606-5945
authorships[14].author.display_name	Gavin Dabrera
authorships[14].affiliations[0].raw_affiliation_string	UKHSA COVID-9 National Epidemiology Cell, London, NW9 5EQ, England
authorships[14].author_position	middle
authorships[14].raw_author_name	Gavin Dabrera
authorships[14].is_corresponding	False
authorships[14].raw_affiliation_strings	UKHSA COVID-9 National Epidemiology Cell, London, NW9 5EQ, England
authorships[15].author.id	https://openalex.org/A5036755484
authorships[15].author.orcid	https://orcid.org/0000-0002-0434-2724
authorships[15].author.display_name	Simon Thelwall
authorships[15].affiliations[0].raw_affiliation_string	UKHSA COVID-9 National Epidemiology Cell, London, NW9 5EQ, England
authorships[15].author_position	last
authorships[15].raw_author_name	Simon Thelwall
authorships[15].is_corresponding	False
authorships[15].raw_affiliation_strings	UKHSA COVID-9 National Epidemiology Cell, London, NW9 5EQ, England
has_content.pdf	True
has_content.grobid_xml	True
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://www.medrxiv.org/content/medrxiv/early/2022/10/22/2022.10.21.22281171.full.pdf
open_access.oa_status	green
open_access.any_repository_has_fulltext	False
created_date	2025-10-10T00:00:00
display_name	Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID-19 cases treated with Sotrovimab in the community in England
has_fulltext	True
is_retracted	False
updated_date	2025-11-06T03:46:38.306776
primary_topic.id	https://openalex.org/T10118
primary_topic.field.id	https://openalex.org/fields/27
primary_topic.field.display_name	Medicine
primary_topic.score	0.9998999834060669
primary_topic.domain.id	https://openalex.org/domains/4
primary_topic.domain.display_name	Health Sciences
primary_topic.subfield.id	https://openalex.org/subfields/2725
primary_topic.subfield.display_name	Infectious Diseases
primary_topic.display_name	SARS-CoV-2 and COVID-19 Research
related_works	https://openalex.org/W2027570649, https://openalex.org/W3213778696, https://openalex.org/W2744105963, https://openalex.org/W4400424401, https://openalex.org/W1967738824, https://openalex.org/W3046070657, https://openalex.org/W2993137968, https://openalex.org/W2994686985, https://openalex.org/W4281722959, https://openalex.org/W1969936139
cited_by_count	17
counts_by_year[0].year	2024
counts_by_year[0].cited_by_count	3
counts_by_year[1].year	2023
counts_by_year[1].cited_by_count	13
counts_by_year[2].year	2022
counts_by_year[2].cited_by_count	1
locations_count	1
best_oa_location.id	doi:10.1101/2022.10.21.22281171
best_oa_location.is_oa	True
best_oa_location.source.id	https://openalex.org/S4306402567
best_oa_location.source.issn
best_oa_location.source.type	repository
best_oa_location.source.is_oa	False
best_oa_location.source.issn_l
best_oa_location.source.is_core	False
best_oa_location.source.is_in_doaj	False
best_oa_location.source.display_name	bioRxiv (Cold Spring Harbor Laboratory)
best_oa_location.source.host_organization	https://openalex.org/I2750212522
best_oa_location.source.host_organization_name	Cold Spring Harbor Laboratory
best_oa_location.source.host_organization_lineage	https://openalex.org/I2750212522
best_oa_location.license	cc-by
best_oa_location.pdf_url	https://www.medrxiv.org/content/medrxiv/early/2022/10/22/2022.10.21.22281171.full.pdf
best_oa_location.version	acceptedVersion
best_oa_location.raw_type	posted-content
best_oa_location.license_id	https://openalex.org/licenses/cc-by
best_oa_location.is_accepted	True
best_oa_location.is_published	False
best_oa_location.raw_source_name
best_oa_location.landing_page_url	https://doi.org/10.1101/2022.10.21.22281171
primary_location.id	doi:10.1101/2022.10.21.22281171
primary_location.is_oa	True
primary_location.source.id	https://openalex.org/S4306402567
primary_location.source.issn
primary_location.source.type	repository
primary_location.source.is_oa	False
primary_location.source.issn_l
primary_location.source.is_core	False
primary_location.source.is_in_doaj	False
primary_location.source.display_name	bioRxiv (Cold Spring Harbor Laboratory)
primary_location.source.host_organization	https://openalex.org/I2750212522
primary_location.source.host_organization_name	Cold Spring Harbor Laboratory
primary_location.source.host_organization_lineage	https://openalex.org/I2750212522
primary_location.license	cc-by
primary_location.pdf_url	https://www.medrxiv.org/content/medrxiv/early/2022/10/22/2022.10.21.22281171.full.pdf
primary_location.version	acceptedVersion
primary_location.raw_type	posted-content
primary_location.license_id	https://openalex.org/licenses/cc-by
primary_location.is_accepted	True
primary_location.is_published	False
primary_location.raw_source_name
primary_location.landing_page_url	https://doi.org/10.1101/2022.10.21.22281171
publication_date	2022-10-22
publication_year	2022
referenced_works	https://openalex.org/W4220848096, https://openalex.org/W4223456653, https://openalex.org/W4221036612, https://openalex.org/W4213171525, https://openalex.org/W3142474203, https://openalex.org/W3198487015, https://openalex.org/W4225553089
referenced_works_count	7
abstract_inverted_index.a	74, 96, 113
abstract_inverted_index.CI	130, 147
abstract_inverted_index.HR	143
abstract_inverted_index.We	46, 72
abstract_inverted_index.at	16
abstract_inverted_index.in	61, 83, 169
abstract_inverted_index.is	3, 159
abstract_inverted_index.it	29, 101
abstract_inverted_index.of	5, 18, 40, 55, 68, 78, 109, 115, 117, 156
abstract_inverted_index.or	52, 90, 119
abstract_inverted_index.to	13, 33, 64, 127
abstract_inverted_index.Cox	98
abstract_inverted_index.and	86, 132, 163
abstract_inverted_index.are	26
abstract_inverted_index.for	124, 133
abstract_inverted_index.had	88
abstract_inverted_index.has	30
abstract_inverted_index.one	4
abstract_inverted_index.the	37, 41, 50, 56, 62, 84, 105, 142, 154, 170
abstract_inverted_index.two	118
abstract_inverted_index.was	102, 122, 140, 144
abstract_inverted_index.(95%	129, 146
abstract_inverted_index.(HR)	108
abstract_inverted_index.0.98	145
abstract_inverted_index.1.17	123
abstract_inverted_index.BA.1	51, 89, 128, 162
abstract_inverted_index.BA.2	38, 53, 91, 125, 164
abstract_inverted_index.been	11
abstract_inverted_index.days	121
abstract_inverted_index.have	10
abstract_inverted_index.more	120
abstract_inverted_index.risk	17, 67, 155
abstract_inverted_index.stay	116
abstract_inverted_index.such	134
abstract_inverted_index.that	9, 28, 104, 153
abstract_inverted_index.with	36, 49, 81, 112, 167
abstract_inverted_index.These	150
abstract_inverted_index.Using	95
abstract_inverted_index.cases	165
abstract_inverted_index.codes	139
abstract_inverted_index.model	100
abstract_inverted_index.study	77
abstract_inverted_index.their	66
abstract_inverted_index.there	25
abstract_inverted_index.treat	14, 34
abstract_inverted_index.where	136
abstract_inverted_index.ICD-10	138
abstract_inverted_index.agents	8
abstract_inverted_index.assess	65
abstract_inverted_index.cohort	76
abstract_inverted_index.either	87
abstract_inverted_index.hazard	106
abstract_inverted_index.length	114
abstract_inverted_index.people	15, 35
abstract_inverted_index.ratios	107
abstract_inverted_index.severe	19
abstract_inverted_index.Methods	71
abstract_inverted_index.Omicron	42, 57
abstract_inverted_index.Results	94
abstract_inverted_index.between	161
abstract_inverted_index.reduced	31
abstract_inverted_index.results	151
abstract_inverted_index.several	6
abstract_inverted_index.similar	160
abstract_inverted_index.suggest	152
abstract_inverted_index.treated	59, 80, 166
abstract_inverted_index.variant	58, 92
abstract_inverted_index.Abstract	0
abstract_inverted_index.COVID-19	22, 137
abstract_inverted_index.However,	24
abstract_inverted_index.compared	47, 126
abstract_inverted_index.concerns	27
abstract_inverted_index.efficacy	32
abstract_inverted_index.hospital	69, 110, 157
abstract_inverted_index.licensed	12
abstract_inverted_index.outcomes	20
abstract_inverted_index.recorded	141
abstract_inverted_index.variant.	45
abstract_inverted_index.admission	111, 158
abstract_inverted_index.community	63, 85
abstract_inverted_index.estimated	103
abstract_inverted_index.following	21
abstract_inverted_index.performed	73
abstract_inverted_index.0.74-1.86)	131
abstract_inverted_index.Conclusion	149
abstract_inverted_index.Objectives	1
abstract_inverted_index.SARS-CoV-2	44
abstract_inverted_index.Sotrovimab	2, 60, 82, 168
abstract_inverted_index.Stratified	97
abstract_inverted_index.admission.	70
abstract_inverted_index.admissions	135
abstract_inverted_index.community.	171
abstract_inverted_index.infection.	23
abstract_inverted_index.regression	99
abstract_inverted_index.(B.1.1.529)	43
abstract_inverted_index.0.58-1.65).	148
abstract_inverted_index.individuals	48, 79
abstract_inverted_index.sub-lineage	39, 54
abstract_inverted_index.therapeutic	7
abstract_inverted_index.retrospective	75
abstract_inverted_index.classification.	93
cited_by_percentile_year.max	99
cited_by_percentile_year.min	89
corresponding_author_ids	https://openalex.org/A5054599845
countries_distinct_count	1
institutions_distinct_count	16
sustainable_development_goals[0].id	https://metadata.un.org/sdg/3
sustainable_development_goals[0].score	0.7699999809265137
sustainable_development_goals[0].display_name	Good health and well-being
citation_normalized_percentile.value	0.86993699
citation_normalized_percentile.is_in_top_1_percent	False
citation_normalized_percentile.is_in_top_10_percent	False